Ivermectin in human medicine, an overview of the current status of its clinical applications

Current Pharmaceutical Biotechnology

Volumn 13, Issue 6, 2012, Pages 1103-1109

  Gonzalez P ^a   Gonzalez F A ^b   Ueno, K ^c  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Filariasis; Human medicine; Ivermectin; Onchocerciasis; Strongyloidiasis

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; IVERMECTIN;

ARTICLE; ASCARIASIS; BRAIN DISEASE; ENTEROBIASIS; FOLLOW UP; GNATHOSTOMIASIS; HUMAN; LOIASIS; LYMPHATIC FILARIASIS; MANSONELOSIS; ONCHOCERCIASIS; PARASITOSIS; PEDICULUS; SCABIES; STRONGYLOIDIASIS; TRICHURIASIS; TRICHURIS TRICHIURA;

MANSONELLA; TRICHURIS TRICHIURA;

EID: 84860498865     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800399248     Document Type: Article

References (109)

1. Centers for Disease Control and Prevention. 1999. Health Information for International Travel 1999-2000. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/onchocerciasis.aspx (Accesed June 10, 2010).
2. World Health Organization. Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control. World Health Organ. Tech. Rep. Ser., 1995, 852, 1-104.
3. Plaisier, A.P.; Alley, E.S.; Boatin, B.A. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J. Infect. Dis., 1995; 172(1), 204-206.
4. Duke, B.O.; Zea-Flores, G.; Castro, J.; Cupp, E.W.; Munoz, B. Comparison of the effects of a single dose and of four six-monthly doses of ivermectin on adult Onchocerca volvulus. Am. J. Trop. Med. Hyg., 1991, 45(1), 132-137.
5. Duke, B.O.; Zea-Flores, G.; Munoz, B. The embryogenesis of Onchocerca volvulus over the first year after a single dose of ivermectin. Trop. Med. Parasitol., 1991, 42(3), 175-180.
6. Awadzi, K.; Addy, E.T.; Opoku, N.O.; Plenge-Bönig, A.; Büttner, D.W. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole. Trop. Med. Parasitol., 1995, 46(4), 213-220.
7. Campbell, W.C. Ivermectin, an antiparasitic agent. Med. Res. Rev., 1993, 13(1), 61-79.
8. Van Laethem, Y.; Lopes, C. Treatment of onchocerciasis. Drugs, 1996, 52(6), 861-869.
9. Gardon, J.; Boussinesq, M.; Kamgno, J.; Gardon-Wendel, N.; Demanga-Ngangue; Duke, B.O. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet, 2002, 360(9328), 203-210.
10. Omura, S. Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents, 2008, 31(2), 91-98.
11. Cupp, E.W.; Duke, B.O.; Mackenzie, C.D.; Guzmán, J.R.; Vieira, J.C.; Mendez-Galvan, J.; Castro, J.; Richards, F.; Sauerbrey, M.; Dominguez, A.; Eversole, R.R.; Cupp, M.S. The effects of longterm community level treatment with ivermectin (Mectizan) on adult Onchocerca volvulus in Latin America. Am. J. Trop. Med. Hyg., 2004, 71(5), 602-607.
12. http://www.mectizan.org/sites/default/files/AH09.pdf. (Accesed December 3, 2010).
13. Brieger, W.R.; Awedoba, A.K.; Eneanya, C.I.; Hagan, M.; Ogbuagu, K.F.; Okello, D.O.; Ososanya, O.O.; Ovuga, E.B.; Noma, M.; Kale, O.O.; Burnham, G.M.; Remme, J.H. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop. Med. Int. Health, 1998, 3(12), 951-961.
14. Tielsch, J.M.; Beeche, A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop. Med. Int. Health, 2004, 9(4), A45-A56.
15. Cupp, E.W.; Ochoa, A.O.; Collins, R.C.; Ramberg, F.R.; Zea, G. The effect of multiple ivermectin treatments on infection of Simulium ochraceum with Onchocerca volvulus. Am. J. Trop. Med. Hyg., 1989, 40(5), 501-506.
16. Collins, R.C.; Gonzales-Peralta, C.; Castro, J.; Zea-Flores, G.; Cupp, M.S.; Richards, F.O.; Cupp, E.W. Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities. Am. J. Trop. Med. Hyg., 1992, 47(2), 156-169.
17. Guderian, R.H.; Anselmi, M.; Espinel, M.; Mancero, T.; Rivadeneira, G.; Proaño, R.; Calvopiña, H.M.; Vieira, J.C.; Cooper, P.J. Successful control of onchocerciasis with community-based ivermectin distribution in the Rio Santiago focus in Ecuador. Trop. Med. Int. Health, 1997, 2(10), 982-988.
18. Dadzie, Y.; Neira, M.; Hopkins, D. Final report of the Conference on the eradicability of onchocerciasis. Filaria J., 2003, 2(1), 2.
19. Awadzi, K.; Attah, S.K.; Addy, E.T.; Opoku, N.O.; Quartey, B.T.; Lazdins-Helds, J.K.; Ahmed, K.; Boatin, B.A.; Boakye, D.A.; Edwards, G. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasisendemic foci in Ghana. Ann. Trop. Med. Parasitol., 2004, 98(4), 359-370.
20. Awadzi, K.; Boakye, D.A.; Edwards, G.; Opoku, N.O.; Attah, S.K.; Osei-Atweneboana, M.Y.; Lazdins-Helds, J.K.; Ardrey, A.E.; Addy, E.T.; Quartey, B.T.; Ahmed, K.; Boatin, B.A.; Soumbey-Alley, E.W. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasisendemic foci in Ghana. Ann. Trop. Med. Parasitol., 2004, 98(3), 231-249.
21. Lymphatic filariasis: the disease and its control. Fith report of the WHO Expert Committee on Filariasis. World Health Organ. Tech. Rep. Ser., 1992, 821, 1-71.
22. Franco-Paredes, C.; Hidron, A.; Steimberg, J. A woman from british Guyana with recurrent back pain and fever. Chyluria associated with infection due to Wuchereria bancrofti. Clin. Infect. Dis., 2006, 42(9), 1297.
23. Ottensen, E.A. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology, 1992, 104(Suppl.), S71-S79.
24. Taylor, M.J.; Cross, H.F.; Ford, L.; Makunde, W.H.; Prasad, G.B.; Bilo, K. Wolbachia bacteria in filarial immunity and disease. Parasite Immunol., 2001, 23(7), 401-409.
25. Cao, W.C.; Van Der Ploeg, C.P.; Paliser, A.P. Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analisis of the effect of single treatment. Trop. Med. Int. Health, 1997, 2(4), 393-403.
26. Addis, D.G.; Beach, M.J.; Strit, T.G.; Lutwick, S.; LeConte, F.H.; Lafontant, J.G.; Hightower, A.W.; Lammie, P.J. Randomized placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaremia in Haitian children. Lancet, 1997, 350(9076), 480-484.
27. Weil, G.J.; Lammie, P.J.; Richards, F.O.; Eberhard, M.L. Changes in circulating parasite levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J. Infect. Dis., 1991, 164(4), 814-816.
28. Dreyer, G.; Noroes, J.; Amaral, F.; Nen, A.; Medeiros, Z.; Coutinho, A.; Addiss, D. Direct assessment of the adulticidal effciacy of a single dose of ivermectin in bancroftian filariasis. Trans. R. Soc. Trop. Med. Hyg., 1995, 89(4), 441-443.
29. Kyelem, D.; Medlock, J.; Sanou, S.; Bonkoungou, M.; Boatin, B.; Molyneux, D.H. Short communication: impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia. Trop. Med. Int. Health, 2005, 10(10), 1002-1004.
30. Nicolas, L.; Plichart, C.; Nguyen, L.N.; Moulia-Pelat, J.P. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J. Infect. Dis., 1997, 175(2), 489-492.
31. Bockarie, M.J.; Alexander, N.D., Hyun, P.; Dimber, Z.; Bockarie, F.; Ibam, E.; Alpers, M.P.; Kazura, J.W. Randomised communitybased trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancroti infection on human beings and mosquitos. Lancet, 1998, 351(9097), 162-168.
32. Andrade, L.D.; Medeiros, Z.; Pires, M.L.; Pimentel, A.; Rocha, A.; Figueredo-Silva, J.; Coutinho, A.; Dreyer, G. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Trans. R. Soc. Trop. Med. Hyg., 1995, 89(3), 319-321.
33. Dreyer, G.; Addiss, D.; Santos, A.; Figueredo-Silva, J.; Norões, J. Direct assesment in vivo of the efficacy of combined single dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. Trans. R. Soc. Trop. Med. Hyg., 1998, 92(2), 219-222.
34. Moulia-Pelat, J.P.; Glaziou, P.; Weil, G.J.; Nguyen, L.N.; Gaxotte, P.; Nicolas, L. Combination ivermectin plus diethylcarbamazine, a new effective tool for control of lymphatic filariasis. Trop. Med. Parasitol., 1995, 46(1), 9-12.
35. Shenoy, R.K.; John, A.; Babu, B.S.; Suma, T.K.; Kumaraswami, V. Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, dithylcarbamazine and albendazole, in various combinations. Ann. Trop. Med. Parasitol., 2000, 94(6), 607-614.
36. Ismail, M.M.; Jayakody, R.L.; Weil, G.J.; Fernando, D.; De Silva, M.S.; De Silva, G.A.; Balasooriya, W.K. Long-term efficacy of single dose combinations of albendazole, ivermectin, and diethylcarbamazine for the treatment of bancroftian filariasis. Trans. R. Soc. Trop. Med. Hyg., 2001, 95(3), 332-335.
37. Richards, F.O.; Pam, D.D.; Kal, A.; Gerlong, G.Y.; Onyeka, J.; Sambo, Y.; Danboyi, J.; Ibrahim, B.; Terranella, A.; Kumbak, D.; Dakul, A.; Lenhart, A.; Rakers, L.; Umaru, J.; Amadiegwu, S.; Withers, P.C.; Mafuyai, H.; Jinadu, M.Y.; Miri, E.S.; Eigege, A. Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria. Ann. Trop. Med. Parasitol., 2005, 99(2), 155-164.
38. Sunish, I.P.; Rajendran, R.; Mani, T.R.; Munirathinam, A.; Reuben, R.; Dash, A.P. Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years. Parasitol. Int., 2006, 55(3), 233-236.
39. De Kraker, M.E.; Stolk, W.A.; Van Habbema, J.D. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop. Med. Int. Health, 2006, 11(5), 718-728.
40. Ottensen, E.A.; Hooper, P.J.; Bradley, M.; Biswas, G. The Global Programme to Eliminate Lymphatic Filariasis: health impact after 8 years. PLoS. Negl. Trop. Dis., 2008, 2(10), 317.
41. Massa, K.; Magnussen, P.; Sheshe, A.; Ntakamulenga, R.; Ndawi, B.; Olsen, A. The combined effect of the Lymphatic Filariasis Elimination Programme and the Schistosomiasis and Soiltransmitted Helminthiasis Control Programme on soil-transmitted helminthiasis in schoolchildren in Tanzania. Trans. R. Soc. Trop. Med. Hyg., 2009, 103(1), 25-30.
42. Freedman D. In: Tropical Infectious Diseases: Principles, Pathogens and Practice; Guerrant, R.; Walker, D.H.; Weller, P.F., Ed; Churchill Livingstone: Philadelphia, 1999; Vol. 2, pp. 873-886.
43. Klion, A.D.; Massougbodji, A.; Sadeler, B.C.; Ottesen, E.A.; Nutman, T.B. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J. Infect. Dis., 1991, 163(6), 1318-1325.
44. Pillay, V.K.; Kirch, E.; Kurtzman, N.A. Glomerulopathy associated with filarial loiasis. JAMA, 1973, 225(2), 179.
45. Martin-Prevel, Y.; Cosnefroy, J.Y.; Ngari, P.; Pinder, M. Reduction of microfilaraemia with single high-dose of ivermectin in loiasis. Lancet, 1993, 342(8868), 442.
46. Martin-Prevel, Y.; Cosnefroy, J.Y.; Tshipamba, P.; Ngari, P.; Chodakewitz, J.A.; Pinder, M. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am. J. Trop. Med. Hyg., 1993, 48(2), 186-192.
47. Gardon, J.; Gardon-Wendel, N.; Demanga-Ngangue; Kamgno, J.; Chippaux, J.P.; Boussinesq, M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet, 1997, 350(9070), 18-22.
48. Boussinesq, M.; Gardon, J.; Gardon-Wendel, N.; Kamgno, J.; Ngoumou, P.; Chippaux, J.P. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am. J. Trop. Med. Hyg., 1998, 58(4), 461-469.
49. Fux, C.A.; Chappuis, B.; Holzer, B.; Aebi, C.; Bordmann, G.; Marti, H.; Hatz, C. Mansonella perstans causing symptomatic hypereosinophilia in a missionary family. Travel Med. Infect. Dis., 2006, 4(5), 275-280.
50. Asio, S.M.; Simonsen, P.E.; Onapa, A.W. Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann. Trop. Med. Parasitol., 2009, 103(1), 31-37.
51. Bregani, E.R.; Rovellini, A.; Mbïdoum, N.; Magnini, M.G. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans. R. Soc. Trop. Med. Hyg., 2006, 100(5), 458-463.
52. Gardon, J.; Kamgno, J.; Gardon-Wendel, N.; Demanga-Ngangue; Duke, B.O.; Boussinesq, M. Efficacy of repeated doses of ivermectin against Mansonella perstans. Trans. R. Soc. Trop. Med. Hyg., 2002, 96(3), 325-326.
53. Richard-Lenoble, D.; Kombila, M.; Chandenier, J.; Gaxotte, P.
54. Van Den Enden, E.; Van Gompel, A.; Van Der Stuyft, P.; Vervoort, T.; Van Den Ende, J. Treatment failure of a single high dose of ivermectin for Mansonella perstans filariasis. Trans. R. Soc. Trop. Med. Hyg., 1993, 87(1), 90.
55. Fischer, P.; Tukesiga, E.; Büttner, D.W. Long-term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin. J. Infect. Dis., 1999, 180(4), 1403-1405.
56. Fischer, P.; Bamuhiiga, J.; Büttner, D.W. Treatment of human Mansonella streptocerca with ivermectin. Trop. Med. Int. Health, 1997, 2(22), 191-199.
57. Keiser, P.B.; Coulibaly, Y.I.; Keita, F.A. Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans. Am. J. Trop. Med. Hyg., 2003, 69(3), 331-335.
58. Stutchler. In: Strongyloidiasis. A Major Roundworm of Man; Grove, D.I., Ed.; Taylor & Francis Ltd.: London, 1989.
59. Keiser, P.P.; Nutman, T.B. Strongyloides stercolaris in the immunocompromised population. Clin. Microbiol. Rev., 2004, 17(1), 208-217.
60. Woodring, J.H.; Halfhill, H.I.I.; Reed, J.C. Pulmonary strongyloidiasis: clinical and imaging features. Am. J. Roentgenol., 1994, 162(3), 537-542.
61. Igual-Adell, R.; Oltra-Alcaraz, C.; Soler-Company, E.; Sánchez-Sánchez, P.; Matogo-Oyana, J.; Rodríguez-Calabuig, D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin. Pharmacother., 2004, 5(12), 2615-2619.
62. Centers of Disease Control and prevention: Strongyloides (Strongyloides stercolaris). http://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/ Strongyloidiasis.pdf (Accesed June 10, 2010).
63. Ardiç, N. [An overview of Strongyloides stercoralis and its infections][Article in Turkish]. Mikrobiyol. Bul., 2009, 43(1), 169-177.
64. Mitsunaga, M.; Miyauchi, N.; Akiyama, Y.; Saima, S. [A case of strongyloidiasis hyperinfection during oral corticosteroid therapy associated with a nephritic patient infected with HTLV-1] [Article in Japanese]. Jp. J. Geriat., 2003, 40(4), 397-401.
65. Mattioni, S.; Valin, N.; Cracco, C.; Thellier, M.; Danis, M.; Caumes, E. Fatal relapse of disseminated strongyloidiasis in an HIV-positive patient, despite ivermectin treatment. Ann. Trop. Med. Parasitol., 2008, 102(8), 693-698.
66. Grein, J.D.; Mathisen, G.E.; Donovan, S.; Fleckenstein, L. Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report. Scand. J. Infect. Dis., 2010, 42(3), 234-236.
67. Turner, S.A.; Maclean, J.D.; Fleckenstein, L.; Greenaway, C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am. J. Trop. Med. Hyg., 2005, 73(5), 911-914.
68. Marty, F.M.; Lowry, C.M.; Rodriguez, M.; Milner, D.A.; Pieciak, W.S.; Sinha, A.; Fleckenstein, L.; Baden, L.R. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin. Infect. Dis., 2005, 41(1), e5-e8.
69. Hauber, H.P.; Galle, J.; Chiodini, P.L.; Rupp, J.; Birke, R.; Vollmer, E.; Zebel, P.; Lange, C. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection, 2005, 33(5-6), 383-386.
70. Salluh, J.I.; Feres, G.A.; Velasco, E.; Holanda, G.S.; Toscano, L.; Soares, M. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. Intensive Care Med., 2005, 31(9), 1292.
71. Chiodini, P.L.; Reid, A.J.; Wiselka, M.J.; Firmin, R.; Foweraker, J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet, 2000, 355(9197), 43-44.
72. Leung, V.; Al-Rawahi, G.N.; Grant, J.; Fleckenstein, L.; Bowie, W. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am. J. Trop. Med. Hyg., 2008, 79(6), 853-855.
73. Page, W.A.; Dempsey, K.; Mccarthy, J.S. Utility of serological follow up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans. R. Soc. Trop. Med. Hyg., 2006, 100(11), 1056-1062.
74. Peters, L.; Mccarthy, A.E.; Faught, C. Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases. Int. J. Infect. Dis., 2009, 13(6), 501-503.
75. Wirk, B.; Wingard, J.R. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl. Infect. Dis., 2009, 11(2), 143-148.
76. Boongird, P.; Phuapradit, P.; Siridej, N.; Chirachariyavej, T.; Chuarihum, S.; Vejjajiva, A. Neurological manifestations of gnathostomiasis. J. Neurol. Sci., 1977, 31(2), 279-291.
77. Punyagupta, S.; Bunnag, T.; Juttijudata, P. Eosinophilic meningitis in Thailand. Clinical and epidemiological characteristics of 162 patients with myeloencephalitis probably caused by Gnathostoma spinigerum. J. Neurol. Sci., 1990, 96(2-3), 241-253.
78. Centers for Disease Control and Prevention: Gnathostomiasis (Gnathostoma soinigerum). http://www.dpd.cdc.gov/dpdx/HTML/gnathostomiasis.htm (Accessed June 10, 2010).
79. Nontasut, P.; Chullawichit, S.; Charoensook, N.; Visesuk, K. Comparison of ivermectin and albendazol treatment for gnathostomiasis. Southeast Asian J. Trop. Med. Public Health, 2000, 31(2), 374-377.
80. Kraivichian, K.; Nuchprayoon, S.; Sitichalernchai, P.; Chaicumpa, W.; Yentakam, S. Treatment of cutaneous gnathostomiasis with ivermectin. Am. J. Trop. Med. Hyg., 2004, 71(5), 623-628.
81. Nontasut, P.; Claesson, B.A.; Dekumyoy, P.; Pakdee, W.; Chullawichit, S. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J. Trop. Med. Public Health, 2005, 36(3), 650-652.
82. Belizario, V.Y.; Amarillo, M.E.; De Leon, W.U.; De Los Reyes, A.E.; Bugayong, M.G.; Macatangay, B.J. A comparison of the efficacy of single doses of albendazole, ivermectin and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull. World Health. Organ., 2003, 81(1), 35-42.
83. Beach, M.J.; Streit, T.G.; Addiss, D.G.; Prospere, R.; Roberts, J.M.; Lammie, P.J. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am. J. Trop. Med. Hyg., 1999, 60(3), 479-486.
84. Marti, H.; Haji, H.J.; Savioli, L.; Chwaya, H.M.; Mgeni, A.F. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg., 1996, 55(5), 477-481.
85. Naquira, C.; Jimenez, G.; Guerra, J.G.; Bernal, R.; Nalin, D.R.; Neu, D.; Aziz, M. Ivermectin for human strongyloidiasis and other intestinal helminths. Am. J. Trop. Med. Hyg., 1989, 40(3), 304-309.
86. Freedman, D.O.; Zierdt, W.S.; Lujan, A.; Nutman, T.B. The efficacy of ivermectin in the chemotherapy of gastrointestinal helminthiasis in humans. J. Infect. Dis., 1989, 159(6), 1151-1153.
87. Ranque, S.; Chippaux, J.P.; Garcia, A.; Boussinesq, M. Follow-up of Ascaris lumbricoides and Trichuris trichiura infections in children living in a community treated with ivermectin at 3-monthly intervals. Ann. Trop. Med. Parasitol., 2001, 95(4), 389-393.
88. Behnke, J.M.; Pritchard, D.I.; Wakelin, D.; Park, J.R.; Mcnicholas, A.M.; Gilbert, F.S. Effect of ivermectin on infection with gastrointestinal nematodes in Sierra Leone. J. Helminthol., 1994, 68(3), 187-195.
89. Moncayo, A.L.; Vaca, M.; Amorim, L.; Rodriguez, A.; Erazo, S.; Oviedo, G.; Quinzo, I.; Padilla, M.; Chico, M.; Lovato, R.; Gomez, E.; Barreto, M.L.; Cooper, P.J. Impact of long-term treatment with ivermectin on the prevalence and intensity of soil-transmitted helminth infections. PLoS. Negl. Trop. Dis., 2008, 2(9), 293.
90. Heukelbach, J.; Wilcke, T.; Winter, B.; Sales de Oliveira, F.A.; Sabóia Moura, R.C.; Harms, G.; Liesenfeld, O.; Feldmeier, H. Efficacy of Ivermectin in a patient population concomitantly infected with intestinal helminthes and ectoparasites. Arzneimittelforschung, 2004, 54(7), 416-421.
91. Wen, L.Y.;Yan, K.L.; Sun, F.H.; Fang, Y.Y.; Yang, M.J.; Lou, L.J. A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China. Acta Trop., 2008, 106(3), 190-194.
92. Naquira, C.; Jimenez, G.; Guerra, J.G.; Bernal, R.; Nalin, D.R.; Neu, D. Ivermectin for human strongyloidiasis and other intestinal helminths. Am. J. Trop. Med. Hyg., 1989, 40(3), 304-309.
93. Ismail, M.M.; Jayakody, R.L. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of Trichuris trichiura infections in Sri Lanka. Ann. Trop. Med. Parasitol., 1999, 93(5), 501-504.
94. Chosidow, O. Clinical practices. Scabies. N. Engl. J. Med., 2006, 354(16), 1718-1727.
95. Hengge, U.R.; Currie, B.J.; Jäger, G.; Lupi, O.; Schwartz, R.A. Scabies: a ubiquitous neglected skin disease. Lancet Infect. Dis., 2006, 6(12), 769-779.
96. Strong, M.; Johnstone, P.W. Interventions for treating scabies. Cochrane database Syst. Rev., 2007, (3), CD000320.
97. Usha, V.; Gopalakrishnam, N. A comparative study of oral ivermectin and topical permethrin cream in treatment of scabies. J. Acad. Dermatol., 2000, 42(2 Pt. 1), 236-240.
98. Centers for disease control and Prevention. Sexually transmitted diseases treatment guidelines 2006. http://www.cdc.gov/std/treatment (Accesed 4, March 2010).
99. Roberts, L.J.; Huffam, S.E.; Walton, S.F.; Currie, B.J. Crusted sabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J. Infect., 2005, 50(5), 375-381.
100. Currie, B.J.; Harumal, P.; McKinnon, M.; Walton, S.F. First documentation of in vivo an in vitro ivermectin resistance in Sarcoptes scabiei. Clin. Infect. Dis., 2001, 39(1), e8-e12.
101. Currie, B.J.; McCarthy, J. Permethrin and ivermectin for scabies. N. Engl. J. Med., 2010, 362(8), 717-725.
102. Dourmishev, A.L.; Dourmishev, L.A.; Schwartz, R.A. Ivermectin: pharmacology and application in dermatology. Int. J. Dermatol., 2005, 44(12), 981-988.
103. Guzzo, C.A.; Furtek, C.I.; Porras, A.G.; Chen, C.; Tipping, R.; Clineschmidt, C.M.; Sciberras, D.G.; Hsieh, J.Y.; Lasseter, K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol., 2002, 42(10), 1122-1133.
104. Nofal, A. Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. J. Dtsch. Dermatol. Ges., 2010, 8(12), 985-988.
105. Asenov, A.; Oliveira, F.A.; Speare, R.; Liesenfeld, O.; Hengge, U.R.; Heukelbach, J. Efficacy of chemical and botanical over-thecounter pediculicides available in Brazil, and off-label treatments, against head lice ex vivo. Int. J. Dermatol., 2010, 49(3), 324-330.
106. Pilger, D.; Heukelbach, J.; Khakban, A.; Oliveira, F.A.; Fengler, G.; Feldmeier, H. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull. World Health Organ., 2010, 88(2), 90-96.
107. Chosidow, O.; Giraudeau, B.; Cottrell, J.; Izri, A.; Hofmann, R.; Mann, S.G.; Burgess, I. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N. Engl. J. Med., 2010, 362(10), 896-905.
108. Munirathinam, A.; Sunish, I.P.; Rajendran, R.; Tyagi, B.K. Impact of ivermectin drug combinations on Pediculus humanus capitis infestation in primary schoolchildren of south Indian rural villages. Int. J. Dermatol., 2009, 48(11),1201-1205.
109. Strycharz, J.P.; Yoon, K.S.; Clark, J.M. A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae). J. Med. Entomol., 2008, 45(1),75-81.